SCHEDULE 13G/A: Nantahala Capital Management Discloses 4.39% Stake in Benitec Biopharma

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has filed an amended Schedule 13G disclosing a 4.39% beneficial ownership stake in Benitec Biopharma Inc. as of March 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") collectively hold beneficial ownership of 1,038,371 shares of Benitec Biopharma Inc. common stock.
• This represents 4.39% of the total outstanding shares of Benitec Biopharma Inc. as of March 31, 2025.
• The reported shares include 200,276 shares that can be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• The Reporting Persons have shared voting and shared dispositive power over all 1,038,371 shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains no subjective language, financial performance data, or strategic updates that would typically influence sentiment. The ownership stake is below 5% and stated to be for ordinary course of business, indicating a passive investment.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Benitec Biopharma Inc.'s future performance or strategic direction, as it is a disclosure of beneficial ownership.

Industry Context

This filing indicates a significant, though non-controlling, investment by an institutional investor in a biopharma company. Such investments are common in the biopharma sector, which often relies on external capital and institutional backing for research, development, and commercialization efforts. The stake is below the 5% threshold that would typically trigger more activist intent, suggesting a passive investment.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which could be viewed positively as a vote of confidence, though the stake is passive and below 5%.

Key Dates

Keywords

Benitec Biopharma Inc., Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Schedule 13G, Beneficial Ownership, Common Stock, Biopharma, Investment Adviser, SEC Filing